Anlon Healthcare Intrinsic Value
Anlon Healthcare (AHCL) median intrinsic value is ₹39.90 from 8 valuation models (range ₹27–₹40), vs current price ₹13.30 — +200.0% upside (Trading Below Calculated Value), margin of safety 66.7%. For current market price and key ratios, visit AHCL stock price BSE.
AHCL Valuation Methods Summary — DCF, Graham Number & P/E
Anlon Healthcare intrinsic value across 8 models vs current price ₹13.30 — upside/downside and value range per method. Also explore Anlon Healthcare stock price data download to track price trends across different timeframes.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹39.90 | ₹31.92 - ₹47.88 | +200.0% | EPS: ₹8.40, Sector P/E: 22x |
| Book Value Method | asset | ₹33.25 | ₹29.93 - ₹36.58 | +150.0% | Book Value/Share: ₹20.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹26.60 | ₹23.94 - ₹29.26 | +100.0% | Revenue/Share: ₹42.50, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹26.60 | ₹23.94 - ₹29.26 | +100.0% | EBITDA: ₹50.00Cr, EV/EBITDA: 10x |
| PEG Ratio Method | growth | ₹39.90 | ₹35.91 - ₹43.89 | +200.0% | EPS Growth: 20.0%, Fair P/E: 16.0x |
| Growth Adjusted P/E | growth | ₹39.90 | ₹35.91 - ₹43.89 | +200.0% | Revenue Growth: 15.0%, Adj P/E: 16.1x |
| ROE Based Valuation | profitability | ₹26.60 | ₹23.94 - ₹29.26 | +100.0% | ROE: 43.8%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹39.90 | ₹35.91 - ₹43.89 | +200.0% | EPS: ₹8.40, BVPS: ₹20.00 |
AHCL Intrinsic Value vs Market Price — All Valuation Models
Anlon Healthcare fair value range ₹27–₹40 vs current market price ₹13.30 across 8 valuation models. Read AHCL dividend growth for the complete payout history and dividend yield track record.
AHCL Intrinsic Value Analysis — Undervalued or Overvalued?
Anlon Healthcare median intrinsic value ₹39.90, current price ₹13.30 — Trading Below Calculated Value by 200.0%, margin of safety 66.7%.
What is the intrinsic value of AHCL?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Anlon Healthcare (AHCL) is ₹39.90 (median value). With the current market price of ₹13.30, this represents a +200.0% variance from our estimated fair value.
The valuation range spans from ₹26.60 to ₹39.90, indicating ₹26.60 - ₹39.90.
Is AHCL undervalued or overvalued?
Based on our multi-method analysis, Anlon Healthcare (AHCL) appears to be trading below calculated value by approximately 200.0%.
AHCL Financial Health — Key Ratios vs Industry Benchmarks
Anlon Healthcare financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 3.88 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 43.8% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 29.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.94x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
AHCL Cash Flow Quality — Operating & Free Cash Flow
Anlon Healthcare operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-23 Cr | ₹-23 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹-3 Cr | ₹-5 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹-3 Cr | ₹-3 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹-2 Cr | ₹-2 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹-15 Cr | ₹-17 Cr | Negative Cash Flow | 3/10 |